ClinicalTrials.gg
RecruitingNCT05785637HPforNIVUpdated Nov 24, 2025

Polygraphy at Home for Neuromuscular Patients Under Non-invasive Mechanical Ventilation

An observational study in Neuromuscular Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Neuromuscular Diseases · Assistance Publique - Hôpitaux de Paris.

Started
2024
with 1 other
Observational
6 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2024, is one of 6 observational ones, and was the 7th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

3 of the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the feasibility, the quality and the utility of a polygraphic control at home in order to appreciate the efficacy of the night time non-invasive ventilation (allowing to optimize the ventilator settings when the results are not satisfactory).

03

Conditions studied

  • Neuromuscular Diseases

Keywords

  • Neuromuscular Diseases
  • Polygraphy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chronic respiratory failure due to neuromuscular diseases under non-invasive mechanical ventilation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient ≥ 18 years;
  • Patient with chronic respiratory insufficiency has just been posed non-invasive ventilation (NIV) in the hospital, according to the latest international recommendations ;
  • Affiliation to the social security scheme;
  • Patient has signed the form to participate to the study.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal;
  • Patient under guardianship;
  • Patient under AME scheme;
  • Patients living more than 40 km from reference center;
  • Patient depending on mechanical ventilation (more than 6 hours daily);
  • Rapidly or reversible evolutive neuro-myopathy (Amyotrophic lateral sclerosis, Guillain Barré syndrome, myasthenia).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No

Groups and cohorts

  • Initiation a non-invasive ventilation at night

    Neuromuscular patients with chronic respiratory failure who initiate a non-invasive ventilation at night.

    Procedure: Polygraphy diagnostic at home

Interventions

  • ProcedurePolygraphy diagnostic at home

    Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.

06

What researchers measure

Primary outcomes

  1. Gradation of quality of recorded signals at home

    Expressed in number of readable signals for which the readability will be expressed in % of record time.

    Time frame: at day 1

07

Study locations

1 of 1 sites recruiting
  • Department of physiology and functional explorations - Raymond Poincaré Hospital - APHP
    Garches, 92380, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2026, 24 months after the start.

Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 24 months is below that.

Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Mar 27, 2023
StartActual
Mar 8, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05785637
Collaborators
Association Française contre les Myopathies (AFM), Paris
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
Mar 8, 2024
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Frédéric Lofaso, MD, PhD
Contact
f.lofaso@aphp.fr
+33 (0)1 47 10 79 41
Hélène Prigent, MD, PhD
Contact
helene.prigent@aphp.fr
+33 (0)1 47 10 79 40
Frédéric Lofaso, MD, PhD
principal investigator · Department of physiology and functional explorations - Raymond Poincaré Hospital - APHP
Hélène Prigent, MD, PhD
study director · Department of physiology and functional explorations - Raymond Poincaré Hospital - APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion